BMY vs. SMMT: Bristol-Myers Squibb vs. Summit Therapeutics Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Summit Therapeutics (SMMT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while SMMT is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Bristol-Myers Squibb (BMY) has a non-negative beta of 0.19.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bristol-Myers Squibb (BMY) reports 44.01%, ranking against industry peers normally.

Bristol-Myers Squibb (BMY) at 18.47% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

Bristol-Myers Squibb (BMY) at 33.79% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Bristol-Myers Squibb (BMY) reports revenue growth of -0.22%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Neither Bristol-Myers Squibb (BMY) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Bristol-Myers Squibb (BMY) at 1.59 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMY.

Summit Therapeutics (SMMT) at 0.04 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Summit Therapeutics (SMMT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bristol-Myers Squibb (BMY) trades at 13.78 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for Bristol-Myers Squibb (BMY), whose P/S ratio of 2.54 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Bristol-Myers Squibb (BMY) at 5.43 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

Valuation Metrics